EU regulators begin review of LEO's IL-13 monoanti-tralokinumab to treat adhetular dermatitis
-
Last Update: 2020-06-16
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
The Eu drug regulator has begun a review of LEO Pharma's leukocyte interleukin 13 (IL-13) monoanti-tralokinumab treatment for moderate to severe adhesional dermatitisThe drug is an all-human monoclonal antibody that neutralises IL-13 cytokine, a potential key driver of ad hoc dermatitisThe application is based on data from key ECZTRA 1, 2 and 3 Phase III studies that assessed the efficacy and safety of traokinumabIn the trial, after 16 weeks of treatment, patients showed clear or almost transparent skin, and at week 16 the eczema area and severity index (EASI) score changed at least 75% or more from the baselineIn addition, the overall rate of adverse events was comparable to that of placebos"People with epitoma dermatitis often face enormous physical, social, and emotional challenges," said Kim Kj?ller, executive vice president of global research and development at LEO Pharma"Since atopic dermatitis is a heterogeneous disease, we focus on targeted treatments to meet individual needs and reduce the burden of disease"
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
